Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AKR1C3-IN-9 is a selective Aldo-keto Reductase 1C3 (AKR1C3) inhibitor (IC50= 8.92 nM). AKR1C3-IN-9 can significantly reverse the Doxorubicin (DOX) resistance in a resistant breast cancer cell line.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 64.00 | |
10 mg | In stock | $ 97.00 | |
25 mg | In stock | $ 197.00 | |
50 mg | In stock | $ 328.00 | |
100 mg | In stock | $ 538.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 70.00 |
Description | AKR1C3-IN-9 is a selective Aldo-keto Reductase 1C3 (AKR1C3) inhibitor (IC50= 8.92 nM). AKR1C3-IN-9 can significantly reverse the Doxorubicin (DOX) resistance in a resistant breast cancer cell line. |
Targets&IC50 | AKR1C3:8.92 nM |
In vitro | AKR1C3-IN-9 (compound 24) (10-100 μ M; 72 h and 96 h) exhibits weak anti proliferation effect on three breast cancer cell lines (MDA-MB-231, MCF-7) with the inhibition range of 100 μ M. AKR1C3-IN-9 (10 μ M, 25 μ M, 50 μ M; 72 hours) and 10-50 μ M DOX synergistically inhibits the proliferation of MCF-7 cells. AKR1C3-IN-9 (10 μ M; 8 d) and 50 μ M DOX synergistically inhibits the proliferation and clonal survival of MCF-7/DOX cell lines, thereby restoring sensitivity to DOX [1]. |
Molecular Weight | 352.38 |
Formula | C20H20N2O4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 75.0 mg/mL (212.8 mM), Sonication and heating to 60℃ are recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AKR1C3-IN-9 Metabolism NADPH inhibitor inhibit